Given that dyslipidemia is a key component of metabolic syndrome, and cardiovascular outcomes are of the utmost importance in managing such patients, a combination approach may yield better results than GLP-1RA monotherapy in this aspect 30
External resources New England Journal of Medicine: Tirzepatide versus semaglutide in type 2 diabetes (SURPASS-2 trial) PMC: Switching between GLP-1 receptor agonists, rationale and practical guidance Endocrine Practice: Switching to tirzepatide from GLP-1 receptor agonists, clinical expectations PMC: The risk of vestibular disorders with semaglutide and tirzepatide In case I do not see you, good afternoon, good evening, and good night
Fatty acid modification of the anticancer peptide LVTX-9 to enhance its cytotoxicity against malignant melanoma cells
Double-punch strategy against triple-negative breast cancer via a synergistic therapy of magneto-mechanical force enhancing NIR-II hypothermal ablation
Indeed, we observed reduced NFB activation [i.e., diminished phospho-IB status (Fig